Amgen Inc. (NASDAQ:AMGN), stock is trading $191.10 above the 52-week high and has displayed a high EPS growth of 20.50% in last 5 years. They now have an overweight rating on the medical research company's stock.
AMGN has been the subject of several research analyst reports. Zacks Investment Research raised shares of Amgen from a "hold" rating to a "buy" rating and set a $166.00 price target on the stock in a report on Wednesday, June 29th. Amgen Inc. The stock has a market capitalization of $124,490.00, a price-to-earnings ratio of 13.70, a PEG ratio of 2.50 and a beta of 1.37. Equity analyst Mizuho updated guidance on AMGN stating a rating of "Buy" and establishing a price target of $198.00. BMO Capital Markets lowered Amgen from an "outperform" rating to a "market perform" rating in a report on Wednesday, July 26th. Thirteen analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of "Buy" and a consensus price target of $190.03. (NASDAQ AMGN) traded down $1.86 during trading hours on Friday, reaching $172.14. About 1.93 million shares traded. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases.
The company has a current ratio of 6.1 gauging towards its ability in paying short-term and long-term obligations. Amgen, Inc. (NASDAQ:AMGN) has risen 5.27% since November 12, 2016 and is uptrending. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. The firm's quarterly revenue was down.7% on a year-over-year basis. Amgen had a net margin of 35.54% and a return on equity of 29.90%. After $0.07 actual earnings per share reported by Amphastar Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -42.86% negative EPS growth.
COPYRIGHT VIOLATION NOTICE: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of worldwide trademark and copyright laws. The original version of this story can be viewed at https://www.truebluetribune.com/2017/11/13/amgen-inc-amgn-cut-to-hold-at-argus.html. As per Wednesday, April 5, the company rating was downgraded by Jefferies. Shares for $451,164 were sold by Patton Cynthia M.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. The ex-dividend date is Monday, November 14th. This represents a $4.60 annualized dividend and a dividend yield of 2.67%. With the existing current ratio, Amgen Inc.is more than equipped to confront its liabilities with its assets.
The stock decreased 0.09% or $0.01 on November 10, reaching $11.61. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company's stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Alpha Omega Wealth Management LLC increased its stake in Amgen by 19.0% in the 1st quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company's stock worth $637,139,000 after purchasing an additional 3,601,087 shares in the last quarter. The Pennsylvania-based Blue Bell Private Wealth Management Llc has invested 0.53% in the stock. The Loudon Investment Management Llc holds 17,838 shares with $3.07M value, up from 12,678 last quarter. Jackson Grant Investment Advisers Inc. increased its stake in Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company's stock worth $104,000 after acquiring an additional 4 shares in the last quarter. $569,541 worth of Amgen, Inc. Finally, Baker Ellis Asset Management LLC bought a new stake in Amgen during the 3rd quarter worth about $108,000. Institutional investors own 78.20% of the company's stock. Hallmark holds 2.14% of its portfolio in Amgen, Inc. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company operates in the human therapeutics segment.